ArticleFrontiers in pharmacology2024

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess.

Yuanbin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.